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Abstract
Background:  There is no validated way of measuring diagnostic delay in cancer, especially
covering patient and primary care delays. An instrument is needed in order to determine the effect
of potential interventions to reduce delay and improve cancer morbidity and mortality.
Methods: Development of a postal questionnaire tool to measure patient and primary care time
responses to key symptoms and signs. The pilot questionnaire was sent to 184 patients with
suspected cancer.
Results: The response rate was only 85/184 (46.2%). Anxiety was cited as one reason for this low
response. Patients returning questionnaires were more likely to be women and more likely to be
younger. 84/85 (98.8%) provided consent to access medical records, and questions regarding health
profile, smoking and socio-economic profile were answered adequately. Outcome data on their
cancer diagnosis was linked satisfactorily and the question about GP-initiated investigations was
answered well. Estimated dates for symptom duration were preferred for patient delays, but exact
dates were preferred for primary care delays; however there was a significant amount of missing
data.
Conclusion: A more personal approach to the collection of data about the duration of symptoms
in this group of people is needed other than a postal questionnaire. However elements of this
piloted questionnaire are likely to figure strongly in future development and evaluation of this tool.
Background
Mortality from cancer is worse in the UK than most other
European countries [1]. Whilst there are several reasons
for this, diagnostic delays and later stage at diagnosis are
likely to be contributory factors. Interventions leading to
reduced diagnostic delays and less advanced stage at diag-
nosis are therefore likely to lead to improved cancer sur-
vival figures and reduced morbidity. However delays at
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various points in the cancer diagnostic journey need map-
ping prior to the development and evaluation of such
interventions. Diagnostic delays (perhaps better referred
to as 'time to diagnosis' since there is not always a 'delay')
may occur at any point in the cancer journey and can be
divided into: pre-symptomatic delays, patient delays, pri-
mary care delays, referral delays, and secondary care
delays [2,3]. The majority of cancer diagnoses are made in
patients who present in primary care with symptoms
[2,3], and the combination of patient and primary care
delays are responsible for at least two thirds of total diag-
nostic delays; significantly more than referral and second-
ary care delays [2,3]. Recent UK government policy
however, has focused primarily on minimising referral
and secondary care delays [4-6], despite a lack of clear evi-
dence for this approach [7-9].
There is no validated tool for determining cancer delays
[10]. Studies reporting patient and primary care delays
have often been methodologically poor and therefore
inaccurate [10]. For example, they have used retrospective
non-validated structured questionnaires (introducing the
potential for recall bias), often with no reference to how
retrospective they are [11] or have used case note review
by surgeons who have used their own judgement to cate-
gorise delays [12]. Most studies that have attempted to
report diagnostic delay have been poor at reporting the
process of data collection.
The pilot study reported here is one step in the process of
developing an appropriate tool to measure cancer delays
from patients' perspectives. The aim of this pilot study was
to achieve the following objectives:
1. To develop and pilot a short self-complete postal ques-
tionnaire for patients with symptoms suggestive of cancer,
including a choice about the way the time to diagnosis
question was asked
2. To develop and test a local protocol for patient recruit-
ment
3. To determine the consent rate for access to medical
records for this sample of patients
Once a tool is developed, appropriate interventions can
be designed and trialled with the objective of reducing
overall delays and reducing cancer mortality and morbid-
ity.
Methods
In this study, patient delay is defined as: 'the time between
the onset of patients' experiences of symptoms which, in
retrospect, they believe to have been due to the cancer,
and presenting these symptoms to primary care', and pri-
mary care delay is defined as: 'the time between the pres-
entation of these symptoms, or others that potentially
may be cancer, in primary care and the onward referral of
the patient to secondary care' [2].
Identification of patients
We identified and recruited adult patients with suspected
cancer from the North East Wales Trust. We worked
closely with the Trust's Cancer Office to identify urgent
suspected referrals. We set out to recruit 190 patients in
order to ensure representation of sufficient numbers of
differing cancer sites. Letters were sent in mid January
2005 to the Cancer Leads of the nine cancer sites and fly-
ers forwarded to general practices that refer patients to
North East Wales Trust informing them of the commence-
ment of the research project. The Cancer Office identified,
on a weekly basis, all adult patients, by cancer site,
referred under the urgent suspected cancer guidance, over
a prospective period for four weeks in early 2005. In total
184 patients were identified.
Data collection from patients
Each identified patient was sent a pack which included a
covering letter with a detailed information sheet inviting
them to open the enclosed sealed envelope if they wished
to take part in the research project or otherwise to return
the pack to a Freepost address. The sealed envelope con-
tained a covering letter welcoming the patient to the
study, a consent form for access to their medical records
and a questionnaire.
Part 1 of the questionnaire was specific to the patient's
suspected cancer site. For each possible symptom for that
cancer site, it asked the respondent how long before they
saw their GP or practice nurse they had had their symp-
toms for, and how long elapsed between presenting their
symptoms and referral. We deliberately asked for
responses to these questions in either of two ways so that
we could determine whether patients preferred to recall
and enter an exact or an estimated date. The list of symp-
toms reflected the symptoms listed in the cancer referral
guidelines for each specific cancer site [6]. Hence we knew
in advance that this sample would be able to provide data
about these symptoms.
Part 2 dealt with health profile (asking respondents
whether they had certain conditions in the past two
years), smoking habits, and socio-economic profile. Gen-
eral comments were invited.
Packs were sent as soon as possible after the urgent referral
was received by the cancer office, and in most cases this
would have been before they were seen in secondary care.
Checks were made by the Cancer Office to ascertain
whether patients had died before reminder letters wereBMC Family Practice 2008, 9:9 http://www.biomedcentral.com/1471-2296/9/9
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sent at three weeks and a second reminder with full study
pack at six weeks. All documents other than the question-
naire were translated into Welsh.
Cancer outcome data
Outcome data were obtained in July 2005 as either diag-
nosed or not diagnosed with cancer.
Data analysis
The data analysis was predominantly descriptive, and ana-
lysed using SPSS; and is presented with the appropriate
statistics.
Results
Response Rate
A total of 85 valid (questionnaires completed and analys-
able) (46.2%) responses were received. A further 56 were
classed as declined responses (e.g. questionnaires
returned unopened and messages via telephone stating
that they did not wish to participate), and there was no
response from 43 patients. The distribution between can-
cer sites is shown in Table 1. More women 66/133
(49.6%) had a valid response compared to 19/51 men
(37.2%). Patients returning valid questionnaires were
slightly younger (mean 58.9 years, median 56.9 years,
with a range from 23.6 to 91.8 years and an inter-quartile
range of 48.4 – 71.4 years) compared to those who did
not (mean 62.8 years, median 66.7 years). Of the 85 valid
responses, 49 (57.6%) responded to the first mailing, 24
(28.2%) to the first reminder, and 12 (14.1%) to the sec-
ond reminder. Telephone calls were received from 16
patients, some with more than one comment. Nine of
these comments were concerned with anxiety associated
with receiving the questionnaire in some way; it was not
possible to distinguish between the responses by patients
with suspected compared with confirmed cancer because
of the small numbers. The others concerned the provision
of information about whether or not they were returning
the questionnaire.
Consent to accessing medical records, Health profile, and Smoking & 
Socio-economic profile
Eighty two of the respondents (96.4%) provided consent
to access their medical records. Non-response to the other
questions was: Health Profile one respondent; smoking –
five respondents; living with a spouse or partner – no
respondents; ethnicity – two respondents; educational
level – seven respondents; Employment status – two
respondents. Detailed responses to these questions are
available from the authors.
Cancer diagnosis outcomes
Twenty nine of 184 (15.8%) patients were diagnosed with
cancer. Thirteen (15.3%) of the responders were diag-
nosed and 16/99 non-responders (16.2%). By cancer site,
there were 10 breast (16%), 5 colorectal (17%), 4 upper
GI (19.0%), 3 urological (33.3%), 3 head & neck
(20.0%), 2 gynaecological (9%), and 2 lung (25.0%).
Symptom data
The numbers of symptoms reported on the questionnaires
is shown in Table 2. This also shows how the respondents
answered the questions about duration of symptoms. One
suspected gynaecological cancer was identified through a
screening trial and was asymptomatic. Because of the
larger number of patients with breast cancer, and the cor-
responding number of symptoms we were able to break
the response down further by symptom. This is shown in
Table 3. The majority of recorded symptoms were those
given in pre-determined categories. A small number of
additional symptoms were recorded by individuals. This
question was answered well, with only minimal missing
data. For the question regarding duration of symptoms,
exact answers were given for 25/152 (16.4%) symptoms,
and estimated answers for 81/152 (53.3%); however for
the question relating to when the symptoms were pre-
sented the figures were exact answers 45/152 (29.6%) and
estimated answers 30/152 (19.7%).
Table 1: Response by suspected cancer site
Cancer site Total Sent Response (%) Declined response No response
Breast 64 38 (59%) 6 20
Colorectal 29 10 (34%) 13 6
Gynaecological 22 11 (50%) 7 4
Head & Neck 15 7 (47%) 4 4
Lung 8 4 (50%) 3 1
Skin 16 7 (44%) 7 2
Upper GI 21 6 (29%) 11 4
Urological 9 2 (22%) 5 2
Total 184 85 (46%) 56 43BMC Family Practice 2008, 9:9 http://www.biomedcentral.com/1471-2296/9/9
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Discussion
As a pilot study, the work reported here has achieved its
three aims. Much has been gained from this work that will
be taken forward to the next phase of the work.
The response to this survey was lower than we had ini-
tially hoped, and much lower than we would need for a
future comprehensive study of delays. For example, The
National Survey of NHS Patients – Cancer achieved a
response of 74% [13], although this sampled patients
with cancer rather than suspected cancer. Several factors
may have contributed to our modest response. The ques-
tionnaire was overcomplicated, mainly because we chose
to ask both exact and estimated dates as part of the pilot-
ing process, and this may have had an adverse effect on
response. Some design features and wording on the pilot
questionnaire were on reflection poor and again may have
had an adverse effect, although it is impossible to quantify
how much of a problem this may have caused. We suspect
that the questionnaire may have generated anxiety in a
small number of people; measures to reduce this may
improve future response. This anxiety may have been gen-
erated in part by feelings of guilt at not presenting earlier
that may have been precipitated by the tool, and may also
have been generated by sampling patients with a 'sus-
pected' diagnosis. There may have been a differential poor
response due to age and ill-health related difficulties,
however it was not possible to assess this due to lack of
available data on non-responders.
We successfully demonstrated that the majority of this
sample of people will consent to provide access to their
medical records. This is similar to other work [14,15]. We
were able to incorporate cancer outcome data. We also
demonstrated that this sample of people will provide data
regarding health, smoking, socio-economic profile, edu-
cation, and GP-initiated investigations. However, a future
version of the tool will use lessons learnt in this pilot to
improve some of the category options. We identified
wording in several places in the questionnaire that could
be significantly improved in a future version.
In the analysis we had to make some assumptions about
the data in order to calculate time periods from approxi-
mate dates. These included approximate date ranges that
were coded as the longer time period (e.g. '3–4 weeks' was
coded as 4 weeks); vague date ranges that were appropri-
ately coded (e.g. 'a few months' was coded as 3 months);
Table 2: Response to exact and estimated time durations by cancer site
Total number of 
symptoms 
reported
How long before your diagnosis did you 
notice this (symptom)?
How long before your diagnosis did you first tell your 
GP or nurse about this (symptom)?
Exact date Estimated date Data missing Exact date Estimated date Data missing n/a
Breast (n = 38) 52 9 30 13 21 11 13 7
Colorectal (n = 10) 16 2 10 4 7 5 3 1
Gynae (n = 11) 14 5 6 3 5 4 5 0
Head & Neck (n = 7) 16 0 9 7 1 2 11 2
Lung (n = 4) 13 3 2 8 0 2 11 0
Skin (n = 7) 17 1 8 8 3 2 11 1
Upper GI (n = 6) 21 5 13 3 8 3 5 5
Urology (n = 2) 3 0 3 0 0 1 2 0
Total (%) 152 25 (16.4%) 81 (53.3%) 46 (30.3%) 45 (29.6%) 30 (19.7%) 61 (40.1%) 16 (10.5%)
Table 3: Response to exact and estimated time durations for breast cancer by symptom
How long before your diagnosis did you notice this 
(symptom)?
How long before your diagnosis did you first tell your GP or nurse 
about this (symptom)?
Exact date Estimated date Data missing Exact date Estimated date Data missing n/a
Lump (n = 30) 7 17 6 15 5 7 3
P a i n  ( n  =  1 9 ) 2 1 1 75554
O t h e r s  ( n  =  3 ) 0211110
Total 9 30 14 21 11 13 7
n = number of patients reporting this symptomBMC Family Practice 2008, 9:9 http://www.biomedcentral.com/1471-2296/9/9
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and approximate dates that were coded as the given fig-
ures (e.g. '14 days approx' was coded as 14 days). The
other important issue was that 13/91 respondents pro-
vided no date of referral or provided an 'out of range' date;
in these instances, the dates were entered from hospital
records. In a very small number of instances, respondents
answered both the exact date and the estimated date;
when this occurred this was taken to be the exact date. If
approximate dates are used in future versions of the tool,
we will have to do similar in order to create continuous
variables for analysis.
Most of the recorded symptoms were those expected from
the urgent referral proformas, as expected. The use of free
text to add additional symptoms worked well; none of the
additional symptoms were prevalent enough to justify a
category of its own in a future version.
As a general rule, estimated dates were preferred for
patient delays, but exact dates were preferred for primary
care delays. This may be because dates for primary care
delays were both more recent and more memorable.
However there was a significant amount of missing data;
this may have been because the forms were confusing and
will be improved in a future version. Whilst the numbers
did not permit a detailed analysis of exact versus esti-
mated by symptom (except for breast), it seemed to be the
case that for more vague and undifferentiated symptoms
(e.g. pain), estimated dates were preferred, whereas for
more finite symptoms (e.g. breast lumps), exact dates
were preferred. These findings will need to be taken into
close consideration when designing a future version of the
questionnaire.
Conclusion
Our main conclusion from this study is that a different
approach to the collection of data about the duration of
symptoms in this group of people is needed other than a
postal questionnaire. We are currently developing a
researcher administered/facilitated version of the tool for
administration within a health care setting, that we envis-
age will have a better response and create less anxiety.
However the elements of the questionnaire pilot reported
here are likely to figure strongly in future development
and evaluation of a validated instrument for measuring
patient and primary care cancer delays.
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